Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Depreciation & Amortization (CF) (2023 - 2026)

CG Oncology posted quarterly Depreciation & Amortization (CF) of $841000.0 for Q1 2026, up 3404.17% year-on-year from $24000.0 in Q1 2025, and down 0.94% on a QoQ basis from $849000.0 in Q4 2025.

CG Oncology (CGON) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $841000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 3404.17% year-over-year to $841000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 4250.0% YoY), and the FY2025 full-year result was $1.4 million, up 4415.62% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $841000.0, down from $849000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $849000.0 in Q4 2025 and bottomed at $4000.0 in Q1 2023.
  • The 4-year median for Depreciation & Amortization (CF) is $14000.0 (2024), against an average of $194583.3.
  • The widest annual swing landed in 2024, when Depreciation & Amortization (CF) changed 0.0%; it then surged 3404.17% in 2026.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $4000.0 in 2023, then soared by 425.0% to $21000.0 in 2024, then jumped by 3942.86% to $849000.0 in 2025, then decreased by 0.94% to $841000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $841000.0 (Q1 2026), $849000.0 (Q4 2025), and $416000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 CG Oncology 5.01 Bn 5.01 Bn -1.88 Mn 841,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 841,000.00
Mar 31, 2026 841,000.00
Dec 31, 2025 849,000.00
Dec 31, 2025 849,000.00
Sep 30, 2025 416,000.00
Sep 30, 2025 416,000.00
Jun 30, 2025 156,000.00
Jun 30, 2025 156,000.00
Mar 31, 2025 24,000.00
Mar 31, 2025 24,000.00
Sep 30, 2024 21,000.00
Sep 30, 2024 21,000.00
Jun 30, 2024 7,000.00
Jun 30, 2024 7,000.00
Mar 31, 2024 4,000.00
Mar 31, 2024 4,000.00
Dec 31, 2023 4,000.00
Dec 31, 2023 4,000.00
Sep 30, 2023 5,000.00
Sep 30, 2023 5,000.00
Jun 30, 2023 4,000.00
Jun 30, 2023 4,000.00
Mar 31, 2023 4,000.00
Mar 31, 2023 4,000.00